Targeting the Toll-like Receptor/Interleukin 1 Receptor Pathway in Human Diseases: Rational Design of MyD88 Inhibitors
Authors:
- Vito RuggieroVRVito Ruggiero
- Claudio SetteCSClaudio Sette
- 1 April 2013
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 13 (2) , 222-226
Abstract
No abstract availableKeywords
Funding Information
- Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- Association for International Cancer Research
- Fondazione Italiana Sclerosi Multipla
This publication has 23 references indexed in Scilit:
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaNature, 2011
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and ImmunityImmunity, 2011
- TLR-signaling NetworksJournal of Dental Research, 2010
- Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signallingNature, 2010
- Targeting TLR/IL-1R Signalling in Human DiseasesMediators of Inflammation, 2010
- Identification of Critical Residues of the MyD88 Death Domain Involved in the Recruitment of Downstream KinasesJournal of Biological Chemistry, 2009
- Pyogenic Bacterial Infections in Humans with MyD88 DeficiencyScience, 2008
- Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesisProceedings of the National Academy of Sciences of the United States of America, 2008
- Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal TumorsGastroenterology, 2007
- Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compoundJournal of Leukocyte Biology, 2007